Avoid common mistakes on your manuscript.
While somatic driver gene mutations are considered the hallmark of cancer, oncogenic mutations have recently been found in non-diseased proliferative tissues, such as endometrial [13], esophageal [10], or skin epithelium [11] but also in low proliferative tissues such as the brain [9]. Those discoveries lead to the hypothesis that the mutational processes giving rise to tumors preexist in normal tissue.
Meningioma oncogenesis is dominated by the occurrence of well-known driver gene mutations that form co-exclusive mutational groups, but 20% of meningiomas do not harbor any somatic mutation [4,5,6]. This assertion leads to the hypothesis of non-mutational initiating events in some cases, and questions us about the early events of meningioma formation in the normal meningeal layers. To date, no study focused on the presence of oncogenic driver mutations in the meninges of healthy individuals. To investigate this point, we studied the presence of low variant allele frequency (VAF) variants in the main driver genes with previously described oncogenic potential in meningiomas and decided to select meninges in the elderly, where there is a significant increased incidence of meningiomas [2].
Meningeal layers were obtained from individuals from the brain donation program of our institution. We analyzed a total of 90 post-mortem meningeal samples derived from 5 individuals with no history of intracranial tumors. For each of the 5 participants, we analyzed 15 dura mater samples (8 at the anterior skull base, 4 at the falx, and 3 at the convexity), 3 arachnoid samples, and one brain control sample (Fig. 1a, Supplementary Methods). Pathological analysis using HE sections (Supplementary Fig. 1) and Ki67 labeling (data not shown) confirmed the absence of meningioma or meningothelial hyperplasia at microscopic level and the absence of Ki67-positive cells. We generated deep-targeted sequencing data (average depth of 1760 × per sample across targeted regions, Supplementary Table 1) using a specific capture device covering intronic and exonic regions of 29 known meningioma-driver genes (Supplementary Table 2) and able to detect main chromosomal gains and losses (chromosome 1, 10, 18, and 22). We used Mutect2 and an in-house specific pipeline to call low VAF somatic variants (Fig. 1b and Supplementary Methods). For each individual, meningeal DNA was compared to brain DNA as control.
We obtained a total of 6493 variants, and conservatively filtered out variants to obtain high-confidence variants (Supplementary Methods). Among the 102 high-confidence variants, we kept only the 30 variants with functional impact (Supplementary Methods, Supplementary Table 3). Four occurred in meningioma major driver genes (one in NF2 and three in TRAF7, Fig. 1c, d, Supplementary Table 3) in 4 separate patients (80% of the individuals). Median VAF for these variants was 0.86%. All four were predicted damaging and pathogenic by multiple algorithms (Fig. 1d and Supplementary Methods) and three of them were already described in meningiomas. Besides, all variants were uniquely found in one sample and none were seen in several samples within the same individual, even for neighbor samples separated only by few millimeters. Importantly, no variant was detected in the main hotspots of other oncogenic genes (AKT1, SMO, PIK3CA, Supplementary Table 4 and Supplementary Methods). To validate our variants, we performed droplet digital PCR (ddPCR) for three variants for which assays were commercially available (NF2 p.Tyr101*, TRAF7 p.Lys615Glu and TRAF7 p. Asn520Ser) (Fig. 1e, Supplementary Fig. 2), which confirmed the presence of the three variants and the respective VAFs.
Somatic mutations associated with cancer can be either driver mutations (able to promote clonal expansion), or passenger mutations that do not confer proliferative advantage. Here, we described the presence of passenger mutations in genes implicated in meningioma (ARID1A, CREBBP, KDM5C, or TP53, Fig. 1c), revealing the mutational profile of the normal meningeal layers. ARID1A, a gene involved in chromatin remodeling processes, was the top-mutant gene in our samples, and is mutated in anaplastic meningiomas [7]. Several studies in normal tissue (colon, skin, or esophagus) already described frequent mutations in this gene before tumor formation [16]. It is unknown whether ARID1A mutations in meningiomas are inherited from normal progenitors without playing a role in cancer progression, or if they could act as a first hit in aggressive meningioma clonal selection. No CNV event (e.g., loss of 22q) was detected in any of our samples (Supplementary Fig. 3).
All together, these results suggest that somatic mutations in driver or passenger genes associated with meningioma tumorigenesis are already present at low VAF in the normal meningeal layers of elderly individuals, without apparent meningeal pathology. The occurrence of the driver mutations may constitute an early event in a pathogenic progression through meningioma formation. The high frequency of somatic mutations in elderly dura mater is in line with the previous reports showing a high rate of karyotype abnormality and somatic mutational signatures suggestive of defective DNA damage repair in dura mater-derived cell lines compared to skin-derived cell lines from the same individual [3]. Our major finding concerns the presence of pathogenic TRAF7 mutations in the anterior skull base dura or arachnoid, mirroring the location of TRAF7-mutant meningiomas and the high expression of TRAF7 in neural crest-derived meninges during embryogenesis [12]. The occurrence of TRAF7 mutations in the normal meninges also questions its intrinsic pathogenic value, since meningiomas frequently harbor a second co-mutation (KLF4K409Q or one of the main oncogenes of the PI3K pathway, AKT1 and PIK3CA) [1, 5]. Our results are in line with the previous reports that suggest that TRAF7 (as well as NF2) mutation is typically an early event acquired first in case of co-mutations [8].
Interestingly, driver mutations were present both in the arachnoid and dura mater samples. As arachnoid cells were present in dura mater samples in small amounts (Supplementary Fig. 1f), it is not possible to determine which cell population harbored the oncogenic mutation. Additional studies are mandatory to determine the cell of origin of meningioma, that could be a quiescent meningeal stem cell physiologically present in both layers, able to proliferate and form different histological subtypes from a single cell of origin [15].
To conclude, our data are in favor of the spatially restricted local expansion of cellular clones that carry passenger and/or driver mutations that remain quiescent until secondary additional mechanisms still to discover trigger the tumoral proliferation. These mechanisms could depend on environmental factors (such as hormonal exposure) and rely on genetic (such as co-mutations) or epigenetic (such as methylation modifications) phenomenon [15]. Our targeted sequencing approach evaluated only genes known to be oncogenic in meningioma, and provides first evidence that oncogenic mutations exist in these genes. Future studies will address the total mutation load of normal meningeal samples and study potential variants in other genes. As a cross-sectional analysis in the elderly, this study does not address the question of mutations in young individuals and the evolution of the meningeal mutational burden with time. Detecting ultra-low mosaic clonal events remains technically challenging, and thus, additional mutations may also exist that bypassed our detection threshold [14]. Future studies addressing the accumulation of genetic variants or other molecular alterations in the normal meningeal layers will help to continue dissecting early mechanisms of meningioma oncogenesis.
References
Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18:649–655. https://doi.org/10.1093/neuonc/nov316
Achey RL, Gittleman H, Schroer J, Khanna V, Kruchko C, Barnholtz-Sloan JS (2019) Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005–2015, using the Central Brain Tumor Registry of the United States. Neuro Oncol 21:380–391. https://doi.org/10.1093/neuonc/noy162
Argouarch AR, Schultz N, Yang AC, Jang Y, Garcia K, Cosme CG et al (2022) Postmortem human dura mater cells exhibit phenotypic, transcriptomic and genetic abnormalities that impact their use for disease modeling. Stem Cell Rev Rep 18:3050–3065. https://doi.org/10.1007/s12015-022-10416-x
Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289. https://doi.org/10.1038/ng.2526
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009
Clark VE, Harmancı AS, Bai H, Youngblood MW, Lee TI, Baranoski JF et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253–1259. https://doi.org/10.1038/ng.3651
Collord G, Tarpey P, Kurbatova N, Martincorena I, Moran S, Castro M et al (2018) An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Sci Rep 8:13537. https://doi.org/10.1038/s41598-018-31659-0
Dogan H, Blume C, Patel A, Jungwirth G, Sogerer L, Ratliff M et al (2022) Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas. Acta Neuropathol 144:799–802. https://doi.org/10.1007/s00401-022-02485-6
Ganz J, Maury EA, Becerra B, Bizzotto S, Doan RN, Kenny CJ et al (2022) Rates and patterns of clonal oncogenic mutations in the normal human brain. Cancer Discov 12:172–185. https://doi.org/10.1158/2159-8290.CD-21-0245
Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ et al (2018) Somatic mutant clones colonize the human esophagus with age. Science 362:911–917. https://doi.org/10.1126/science.aau3879
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S et al (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880–886. https://doi.org/10.1126/science.aaa6806
Mishra-Gorur K, Barak T, Kaulen LD, Henegariu O, Jin SC, Aguilera SM et al (2023) Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease. Proc Natl Acad Sci USA 120:e2214997120. https://doi.org/10.1073/pnas.2214997120
Moore L, Leongamornlert D, Coorens THH, Sanders MA, Ellis P, Dentro SC et al (2020) The mutational landscape of normal human endometrial epithelium. Nature 580:640–646. https://doi.org/10.1038/s41586-020-2214-z
Salk JJ, Schmitt MW, Loeb LA (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269–285. https://doi.org/10.1038/nrg.2017.117
Tomasetti C, Li L, Vogelstein B (2017) Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355:1330–1334. https://doi.org/10.1126/science.aaf9011
Wijewardhane N, Dressler L, Ciccarelli FD (2021) Normal somatic mutations in cancer transformation. Cancer Cell 39:125–129. https://doi.org/10.1016/j.ccell.2020.11.002
Acknowledgements
The authors would like to thank the following associations: ARSLA, CSC, France DFT, Fondation ARSEP, Fondation Vaincre Alzheimer, France Parkinson. The Neuro-CEB Neuropathology network includes: Dr. Franck Letournel (CHU Angers), Dr. Marie-Laure Martin-Négrier (CHU Bordeaux), Dr. Maxime Faisant (CHU Caen), Pr. Catherine Godfraind (CHU Clermont-Ferrand), Pr. Claude-Alain Maurage (CHU Lille), Dr. Vincent Deramecourt (CHU Lille), Dr. Mathilde Duchesne (CHU Limoges), Dr. David Meyronnet (CHU Lyon), Dr. Clémence Delteil (CHU Marseille), Pr. Valérie Rigau (CHU Montpellier), Dr. Fanny Vandenbos-Burel (Nice), Pr. Danielle Seilhean (CHU PS, Paris), Dr. Susana Boluda (CHU PS, Paris), Dr. Isabelle Plu (CHU PS, Paris), Dr. Dan Christian Chiforeanu (CHU Rennes), Dr. Florent Marguet (CHU Rouen), and Dr. Béatrice Lannes (CHU Strasbourg).
Funding
This work was supported by a grant from the Fondation de l’Avenir to Matthieu Peyre (Project No. AP-RM-21015).
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The members of The Brainbank Neuro-CEB Neuropathology Network are listed in Acknowledgements.
Supplementary Information
Below is the link to the electronic supplementary material.
401_2023_2635_MOESM4_ESM.xlsx
Supplementary Table 3: Table of the 30 variants remaining after variant calling and exclusion of non-functionally significant variants. Algorithms: MT: Mutect2; LF: Samtools1-10 mpileup; ST: Strelka 2.9.10 (see Supplementary methods). (XLSX 14 kb)
401_2023_2635_MOESM5_ESM.xlsx
Supplementary Table 4: Table of the results of the sequencing on the main hotspots in meningioma-driver genes. (XLSX 38 kb)
401_2023_2635_MOESM6_ESM.tiff
Supplementary Fig. 1. Histological analysis of arachnoid (a, b, c) and dura mater (d, e, f) samples. Whole samples for arachnoid and dura mater are displayed in a. and b. respectively (scale bars 2 mm), revealing the global architecture of each tissue. Arachnoid tissue presented a majority of areas with typical meningothelial architecture (b., scale bar 100 μm) but also several blood vessels (asterisks in c., scale bar 100 μm). Dura mater samples presented with typical collagen fibers (e. scale bar 100 μm) but occasionally displayed small inclusions of arachnoid cells with round nuclei and clear cytoplasm (black arrow heads in f., scale bar 100 μm). (TIFF 33631 kb)
401_2023_2635_MOESM7_ESM.tiff
Supplementary Fig. 2. NF2 and TRAF7 mutations in normal meninges detected by ddPCR. Two dimensional ddPCR plots of TRAF7-mutant meningeal samples and meningioma controls. The wild type and mutant droplets for each mutation are displayed on the X and Y axis, respectively. For each sample, the number of mutant and wild type droplets are indicated at the top left and bottom right corners, respectively. (TIFF 35160 kb)
Rights and permissions
About this article
Cite this article
Boetto, J., Plu, I., Ducos, Y. et al. Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes. Acta Neuropathol 146, 833–835 (2023). https://doi.org/10.1007/s00401-023-02635-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-023-02635-4